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Summary Shiga toxin (ST) is a protein toxin o^ Shigella dysenteriae type 1, a causative agent of severe
diarrhoea and dysentery. In this report we describe the gastrointestinal secretory antibody response of
mice following orogastric immunization with ST. Gastrointestinal secretions were sampled by a gas-
trointestinal lavage technique weekly for 5 weeks after initial immunization. Assay of lavage samples by
ELISA showed that mice vaccinated orogastrically with various doses of ST developed gastrointestinal
antibody to ST in a dose-dependent manner. Serum anti-ST activity developed by 5 weeks after initial
immunization. The ability of ST to act as a mucosal immune adjuvant was investigated by coadminis-
tration of ST and keyhole limpet haemocyanin. In contrast to cholera toxin, a potent adjuvant, ST did
not demonstrate adjuvant activity. The mouse gastrointestinal lavage model could be useful for further
analysis of the cellular basis of ST immunogenicity.
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Introduction
The mucosal surfaces of the body, especially those
lining the gastrointestinal, respiratory and genito-
urinary tracts, are continuously exposed to a wide
variety of potentially pathogenic agents including vi-
ruses, bacteria, protozoa and toxins. In response,
plasma cells in the mucosa are directed to synthesize
and secrete antigen specific antibody.' At mucosal sur-
faces, the predominant antibody isotype is secretory
IgA, while IgG predominates in serum. In either case,
antibody can bind to and may inhibit harmful activity
of encountered pathogenic agents.
Shiga toxin (ST) is a protein product of Shigella
dysenteriae type 1, a causative agent of severe diar-
rhoea and dysentery.'"^ In addition, ST has been impli-
cated in the development of haemolytic uraemic syn-
drome.'*^'" It is believed that ST may induce disease by
damaging vascular endothelium.^"^
Although the exact role of ST in clinical disease
remains undefined, the toxic effects of ST have been
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described in several experimental models. The toxin is
lethal for rabbits and mice when given paren-
terally,'^" results in fluid accumulation in acutely
ligated rabbit ileal loops,'" '^ and is cytotoxic for vari-
ous cell lines including human vascular endothelial
cells,''^•'''"'^ ST appears to act by binding of a prote-
olytically generated subunit to the 60S ribosome with
subsequent inhibition of protein synthesis and cell
death.' '
ST is structurally similar to cholera toxin (CT), a
powerful adjuvant for the mucosal immune system, in
that both are multimeric proteins composed of five B
subunits which presumably bind to susceptible cells
and a single A subunit believed responsible for gener-
ating a toxic subunit following endocytosis,'^'^
Systemic humoral immunity to ST is readily stimu-
lated and immune sera from humans and rabbits can
neutralize in vitro activity of the toxin."'^•-' The protec-
tive value of serum anti-ST antibody is questionable as
demonstrated by failure of high circulating anti-ST
titres to protect Rhesus monkeys against clinical
shigellosis when orally challenged with live Shigella
dysenteriae.'^^ Although these studies clearly describe
the serum antibody response to ST, there is a lack of
data describing local immunity in the gastrointestinal
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tract. Studies in rabbits have shown that, like CT, ST
stimulates a powerful antigen specific secretory IgA
response when administered directly into Thiry-Vella
ileal loops.'- Furthermore, anti-ST secretory IgA in-
hibits HeLa cell cytotoxicity and fluid accumulation in
acutely ligated rabbit ileal segments.'^
Precise definition of the cellular basis for stimu-
lation of the gastrointestinal antibody response to ST
has been hampered by the expense and effort of using
the rabbit Thiry-Vella ileal loop model, the lack of
inexpensive inbred lines of rabbits, and the lack of
readily available monoclonal antibodies to rabbit lym-
phocyte antigens. In this regard, an easily manipulated
mouse model to study the mucosai immune response
to ST would be useful. Described here is the applica-
tion of a mouse orogastric lavage technique to investi-
gate dose sensitivity of the gastrointestinal anti-ST
secretory IgA response, development of this response
over time, and studies to determine if ST, like CT, can
exert an adjuvant effect for a weak mucosal protein
antigen, keyhole limpett haemocyanin (KLH)."'
Materials and methods
Immunogens
CT was obtained from List Biological Laboratories
Inc. (Campbell, CA, USA). Purified ST used for immu-
nization of mice was prepared by affinity column chro-
matography as described in detail elsewhere."^ Purified
ST used as antigen in ELISA assays was prepared from
the ammonium sulfate precipitate of culture lysates
from S. dysenteriae by using a combination of ion-
exchange chromatography, gel filtration chromatogra-
phy and preparative isoelectric focusing.'^
Animals
Eight to twelve week old C57B1/6J female mice from
the Jackson Laboratory (Bar Harbor, ME, USA) were
used in all animal studies. All mice were specific patho-
gen free and were housed under conditions suitable to
maintenance of a constant microbiologic status. Use of
these animals was approved by the institutional animal
care and use committee.
Immunizations
To examine the dose sensitivity of the gastrointestinal
secretory IgA response to ST, groups of five mice were
dosed orogastrically with 0.01,0.10, 1.0, 10.0, 25.0 or
50.0 \i% of ST in 0.5 mLof 0.2 mol/L NaHCO_, via a 22
gauge stainless steel feeding needle at days 0, 7, 14 and
21.
To examine the adjuvant activity of ST, groups of
five mice were dosed orogastrically as described above
with 0.5 mL of 0.2 mol/L NaHCO, solutions contain-
ing 5 mg KLH (Sigma Chemical Co., St Louis. MO,
USA), 5 mg KLH and lO^gCT, 5 mg KLH and 10ng
ST, 10 |ig CT or 10 ̂ g ST. In addition, one cohort was
dosed with only 0.5 mL of 0.2 mol/L NaHCO3.
Collection of gastric lavage samples
Gastrointestinal contents were sampled prior to immu-
nization and then weekly for 5 weeks following initial
immunization by a previously described orogastric la-
vage technique."^ Brieffy, mice were orogastrically
dosed via a 22 gauge stainless steel feeding needle four
times, 15 min apart, with 0.5 mL of a hyperosmotic
solution consisting of 0.025 mol/L NaCl, 0.040 mol/L
Na.SOj, 0.01 mol/L KCl, 0.002 mol/L NaHCO, and
0.0485 mol/L polyethylene glycol. Thirty minutes after
the last lavage, each mouse received 0.5 mLof lactated
Ringer's solution subcutaneously and 1,0 mL of 0.1%
(w/v) pilocarpine intraperitoneally. Intestinal se-
cretions were collected over the next 60 min in 3 mL of
0.1% (w/v) soybean trypsin inhibitor. The samples
were diluted to 6 mL with PBS and centrifuged at
600^? for 10 min to remove gross faecal debris. Thirty
microlitres of 17% (w/v) phenylmethylsulfonylfluoride
(PMSF) in 95% (v/v) ethanol was added to the super-
natant prior to centrifuging at 27 000^ for 20 min at
4°C. Next, 1% sodium azide (w/v) and PMSF were
added to the resulting supematant. After incubating
15 min at room temperature, 50 îL of fetal calf
serum/mL of sample were added and the samples were
frozen at - 2 0 ^ .
Collection of serum samples
Blood samples were collected by retro-orbital bleedtng
of mice under methoxyfluorane anaesthesia (Meto-
fane. Pitman-Moore, Washington Crossing. NJ, USA)
prior to immunization and 5 weeks after initial immu-
nization. Sera were stored at - 2O'C.
Enzyme-linked immunosorbent assay
Sera and gastrointestinal lavage samples were assayed
in duplicate for anti-KLH, and anti-ST IgA, IgG and
IgM via an ELISA technique. Polystyrene microdi-
lution wells were coated with either K.LH (1.0 |ag/well)
in 200 mmol/L carbonate buffer (pH 9.6), or pure ST
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{25 ng/well) in carbonate buffer. Following overnight
incubation, the plates were washed three times with
PBS, pH 7.4, containing 0.1% (v/v) Tween 20, and
post-coated with 3% (w/v) bovine serum albumin
(Sigma Chemical Co., St Louis. MO. USA). Following
removal of unbound protein by washing with PBS/
Tween. the plates were stored at 4°C for up to 2 weeks.
Protein concentrations of gastrointestinal lavage and
serum samples were measured by the Bradford method
and standardized by dilution with PBS. Immediately
prior to addition of serum or intestinal secretions, the
antigen solutions were removed and the wells were
again washed with PBS/Tween 20. Samples to be as-
sayed were diluted in this buffer (1:2 for intestinal
lavage samples and 1 : 10 for sera), added to wells
(100|iL/weU) and incubated for 12 h. Following this
incubation, the wells were washed with the buffer and
incubated overnight at 4 X with 1 : 1000 (v/v) sol-
utions containing either alkaline phosphatase conju-
gated rabbit anti-mouse IgG, alkaline phosphatase
conjugated rabbit anti-mouse IgM or alkaline phos-
phatase conjugated goat anti-mouse IgA (Zymed Inc..
South San Francisco, CA, USA) in PBS/Tween 20.
Monospecificity of IgG and IgM antisera was con-
firmed with ELISA. Slight anti-IgM activity in the anti-
IgA reagent was adsorbed out by adding 1 : 2000 (v/v)
mouse IgM (Sigma Chemical, St Louis, MO, USA).
For anti-KLH assays, plates underwent an additional
wash with buffer and the substrate reaction was carried
out with 0.1 mL of p-nitrophenyl phosphate (I mg/
mL) in carbonate buffer at a constant temperature of
2 5 ^ . The kinetics of the enzyme-substrate reaction
were measured to 100 min on a Titertek Multiscan
MicroELISA Reader (Flow Laboratories Inc.. McLean,
VA, USA) at an optical density of 405 nm (OD 405).
For the anti-ST assay, an ELISA Amplification System
(Bethesda Research Laboratories, Gaithersburg, MD,
USA) was used in which plates underwent an initial
reaction with nicotinamide adenine dinucleotide phos-
phate (NADPH) followed by reaction with iodoni-
trotetrazolium violet (INT-violet). Final incubation
with substrate was carried out at a constant tempera-
ture of 25X. Optical density at 490 nm (OD 490) of
the reaction was measured 30 min after addition of
substrate.
Statistical analysis
Means and standard errors of ELISA absorbance
values were compared using the Wilcoxon rank sum
test. Statistical significance was reached when
P<0.05.
Results
Mucosal immune response to ST
Mice inoculated orogastrically with ST mounted a
strong dose-dependent intestinal anti-ST secretory IgA
response (Fig. 1). Two weeks following initial inocu-
lation, mice dosed with 1.0-25 ng of ST began to de-
monstrate significantly elevated anti-ST sIgA titres
which continued to increase through the fourth and
fifth weeks.
A weak anti-ST IgG response was detected in the
intestinal secretions (data not shown), however anti-ST
IgM activity was not found. No blood was grossly
visible in any of the samples. Control mice dosed with
NaHCO3 did not develop significant anti-ST antibody
activity (data not shown).
Four of five animals dosed with 50 iig of ST died
within 2 days after the initial immunization, presum-
ably due to toxic effects of ST. The single surviving
animal from this cohort had a weak anti-ST response.
Serum antibody response to orally administered ST
Five weeks following orogastric administration of
0.1 ng or greater doses of ST. serum anti-ST IgG ac-
tivity increased markedly (Fig. 2). This activity was
significantly greater than pre-immunization anti-ST ac-
tivity in groups dosed with i .0 [ig or more of ST. Im-
munization with at least 1.0 (ig of ST also stimulated
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Fig. 1. Gastrointestinal anti-ST IgA activity for 5 weeks fol-
lowing initial immunization (week 0). Dose groups are
0.01 ^gST(B),o.io^gST(Ea), l.OngST(a). lo.
and 25.0 ^g ST (D).
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Fig. 2. Serum anti-ST IgG activity prior to immunization
and at the time of killing (5 weeks after initial immunization).
Dose groups are 0.01 îg ST (•), O.lO^g ST (M), LO^tg ST
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Fig.3. Gastrointestinal anti-KLH I&A activity through 5
weeks following initial immunization (week 0). Dose groups
are NaHCOj (•). KLH (^), KLH + ST (B), KLH + CT
(Q). and KLH + ST + CT (D).
shown). Mice dosed with 0.01 ^g of ST did not mount a
serum anti-ST response. Interestingly, mice dosed with
25 jig of ST mounted a significantly weaker serum IgG
anti-ST response than those dosed with 10 jig.
Role ofSTas a mucosal immune adjuvant
Having established ST as a strong mucosal immuno-
gen in the mouse, we examined whether ST shared
with CT the ability to act as a mucosal immune
adjuvant. In this regard, mice were dosed with KLH,
a weak mucosal immunogen. alone or in combination
with ST or CT. As expected, mice dosed with KLH
and CT developed significantly elevated anti-KLH
sIgA activity by the third week after initial inocu-
lation. This response experienced further significant
increases during the fourth and fifth weeks (Fig. 3).
Mice dosed with KLH, CT and ST developed anti-
KLH sIgA activity which did not significantly differ
from mice dosed with KLH and CT. In contrast, mice
dosed with NaHCO3, CT, ST or KLH alone or KLH
in combination with ST did not demonstrate signifi-
cantly elevated anti-KLH sIgA activity over the
course of the study. Similarly, anti-KLH gastrointesti-
nal IgG activity was significantly enhanced in mice
dosed with KLH and CT, but not in mice dosed with
KLH alone or in combination with ST (data not
shown). These results indicate that ST lacks the abil-
ity to act as an adjuvant for the mucosal immune
response to KLH.
Discussion
ST is likely an important vinalence factor of Shigella
dysenteriae, the causative agent of human dysentery.
Like CT, a powerful mucosal antigen and adjuvant,
ST elicits a strong secretory IgA response to itself
following administration into rabbit Thiry-Vella ileal
loops.'^"^'^^ The purpose of the present study was to
develop a mouse model in which to study gastrointes-
tinal immunity to ST and to examine the time course
of the anti-ST gastrointestinal antibody response fol-
lowing orogastric immunization.
Anti-ST intestinal IgA and IgG activity developed
in a dose-dependent manner in response to orogastric
immunization with ST. Previous studies conducted in
the rabbit chronic Thiry-Vella ileal loop model found
that anti-ST sIgA activity is detectable by ELISA by
the first week following direct intraloop immunization
and increases after the second and third weekly doses.
We found that in the mouse intestinal lavage model
similar activity is detectable by the second week
following orogastdc immunization with ST. It is inter-
esting that IgG directed against ST was found in
gastrointestinal lavage samples following immuniz-
ation. Although no blood was grossly observable in
these samples, it is possible that small amounts of
undetected blood were present. Alternatively, pilo-
carpine could result in transepithelial transport of
serum components such as IgG, since cholinergic
agents have been shown to cause transient opening of
tight junctions in the gut.~^
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Interestingly, mice dosed with 25 ng of ST had lower
serum anti-ST IgG activity than mice immunized with
10.0 |ig ST. A possible explanation might be the devel-
opment of systemic tolerance to ST. Systemic tolerance
following orogastric exposure has been described for
several protein antigens.~^"^' For many antigens,
larger doses result in a greater and longer-lasting state
of tolerance.
The mouse intestinal lavage model holds several
advantages over the rabbit Thiry-Vella ileal loop
model for the study of the mucosal antibody response
to ST. First, greater numbers of animals can be
studied using the mouse model, since it is less expen-
sive and cumbersome than the surgically manipulated
rabbit model. Second, the availability and use of
inbred strains of mice diminish individual variation,
due to genetic heterogeneity, in response to antigens.
Third, commercial monoclonal antibodies to specific
mouse T-cell antigens and cytokines are readily avail-
able and will permit a thorough investigation of the
cellular basis of ST immunogenicity. Fourth, the oral
route of antigen administration more closely mimics
the natural route of antigen exposure than exposure
through a surgically created, isolated intestinal loop
system.
Previous investigators have described the ability of
CT to enhance the mucosal antibody response to a
variety of unrelated antigens.^^-*^ The exact mechan-
ism by which CT exerts this effect is unknown.
Although several studies have suggested that adjuvan-
ticity occurs through a cAMP independent pathway,
other evidence suggests that this effect may be medi-
ated through elevation of intracellular cAMP.̂ -*"̂ *̂  In
the present study, ST was unable to enhance the
mucosal antibody response to a weak, coadminis-
tered, protein antigen (i.e. KLH). These results show
that although ST is similar to CT in that it is both a
strong immunogen and a multimeric enteric bacterial
toxin, it may not be an adjuvant for the mucosal
immune system. Further studies will be needed to
determine if ST demonstrates adjuvancy for antigens
other than KLH.
In conclusion, ST is a potent oral immunogen in
mice, but lacks adjuvanticity. Although the precise
role of ST in clinical disease remains largely specu-
lative, the antigenicity of ST following orogastric
immunization warrants further study to examine the
potential usefulness of ST in immunization strategies
to protect against Shigella-associaXed disease. Estab-
lishment of the mouse as an animal model in which to
study gastrointestinal immunity to ST will permit a
more detailed examination of the cellular basis of this
response.
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